))
August 2, 2025 - Life Sciences Weekly Recap
Manage episode 497935297 series 3663442
Content provided by Matthew Davison. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Matthew Davison or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Life Sciences Weekly - Episode 9
Recorded: August 2, 2025
Join us for Episode 9 of Life Sciences Weekly as we break down a week of volatility and progress across biotech, pharma, and medtech. With all major sector ETFs sliding—XBI down 2%, XPH off nearly 4%, and XHE dipping close to 4%—we spotlight sharp stock swings from Sarepta’s big rebound to Novo Nordisk’s record plunge.
This episode covers the latest FDA clearances, from rapid COVID-19 diagnostics and wearable heart monitors to innovative radiotherapy platforms and single-use gastroscopes. On the drug front, we highlight new approvals for rare diseases, vision impairment, and generic antidepressants, plus expanded uses for leading therapies and safety label updates for top vaccines and biologics.
We also report on rigorous FDA enforcement actions, major funding rounds in AI and radiopharma, and high-impact M&A—including Sanofi’s China deal for an RNAi rare disorder drug and Monogram Technologies’ historic autonomous robotic knee surgery, setting the stage for the future of orthopedic care.
Don’t miss this week’s industry spotlight on medtech innovation, where AI, robotics, and advanced imaging are converging to revolutionize precision surgery and patient outcomes. Tune in for expert analysis, market movers, regulatory milestones, and the trends shaping the future of life sciences. Stay curious and be well!
With your Life Sciences Industry Guide, Matt Davison
9 episodes
Share
